Related Experiment Videos
New leupeptin analogues: synthesis and inhibition data
R M McConnell1, G E Barnes, C F Hoyng
1Department of Chemistry, University of Arkansas, Pine Bluff 71601.
Journal of Medicinal Chemistry
|January 1, 1990
Summary
Researchers synthesized tripeptide analogues of leupeptin and tested their enzyme inhibition. The modified analogues showed varied effectiveness against trypsin, plasmin, and kallikrein, with specific sequences influencing inhibitory activity.
Area of Science:
- Biochemistry
- Medicinal Chemistry
Background:
- Leupeptin is a known protease inhibitor.
- Understanding protease inhibition is crucial for developing therapeutics.
Purpose of the Study:
- To synthesize and evaluate novel tripeptide analogues of leupeptin.
- To investigate the structure-activity relationships of these analogues as enzyme inhibitors.
Main Methods:
- Synthesis of tripeptide analogues with C-terminal argininal, lysinal, or ornithinal units.
- Enzyme inhibition assays using trypsin, plasmin, and kallikrein.
Main Results:
- (Benzyloxycarbonyl)-L-leucyl-L-leucyl-L-argininal showed moderate inhibition of all tested enzymes.
- (Benzyloxycarbonyl)-L-leucyl-L-leucyl-L-lysinal and (benzyloxycarbonyl)-L-leucyl-L-leucyl-L-ornithinal displayed distinct inhibition profiles.
- (Benzyloxycarbonyl)-L-leucyl-L-leucyl-L-ornithinal selectively inhibited kallikrein.
- Modifications at P2 and P3 positions altered inhibitory activity, with plasmin favoring specific dipeptide units.
Conclusions:
- The C-terminal amino acid and P2/P3 residues significantly impact the inhibitory profile of leupeptin analogues.
- Specific analogues demonstrate potential for targeted inhibition of proteases like kallikrein.